Samumed out-licenses IPF drug candidate

17 September 2018

Privately-held US biopharma firm Samumed has entered an exclusive license agreement for North American rights to its SM04646, being developed for the treatment of idiopathic pulmonary fibrosis (IPF), with United Therapeutics Corp (Nasdaq: UTHR).

Deal terms include $10 million up-front, plus up to $340 million in developmental milestones and up to low double-digit royalties to be paid by United Therapeutics.

Just last month, Samumed concluded its Series A fundraising campaign having raised $438 million based on a valuation of $12 billion. Despite the scale of its success — hitting the $10 billion mark - sees Samumed join the rarified club of "decacorns," alongside AirBNB, Dropbox, Uber and Snapchat — Samumed remains coy about the identities of its investors this time round, observers noted at the time. Its angel investors included IKEA and a host of anonymous, high-wealth individuals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK